PCT WORLD ORGANISATION FOR INTELLECTUAL PROPERTY
International Office
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification[6] : C07K 9/00, C07D 487/04, A61K 31/02, C07D 401/04, C07H 15/203

A1

(11) International publication number: WO 96/31532

(43) International publication date: 10 October 1996 (10.10.96)

(21) International application number: PCT/EP96/01279

(22) International filing date: 22 March 1996 (22.03.96)

(30) Data relating to the priority:
195 12 484.7 4 April 1995 (04.04.95) DE

(71) Applicant (for all designated States except US): BAYER AKTIENGESELLSCHAFT [DE/DE]; D-51368 Leverkusen (DE).

(72) Inventors; and
(75) Inventors/Applicants (US only): Hans-Georg LERCHEN [DE/DE]; Morgengraben 14, D-51061 Cologne (DE). Karsten VON DEM BRUCH [DE/DE]; Bonifatiusstrasse 2, D-51375 Leverkusen (DE). Uwe PETERSEN [DE/DE]; Auf dem Forst 4, D-51375 Leverkusen (DE). Jörg BAUMGARTEN [DE/DE]; Henselweg 13, D-42115 Wuppertal (DE). Norbert PIEL [DE/DE]; Neuenhausstrasse 28, D-40699 Erkrath (DE). Horst-Peter ANTONICEK [DE/DE]; Brahmsstrasse 2A, D-51467 Bergisch Gladbach (DE). Walter WEICHEL [DE/DE]; Dhünner Aue 15, D-51519 Odenthal (DE). Michael SPERZEL [DE/DE]; Normannenstrasse 31, D-42275 Wuppertal (DE). Klaus Dieter BREMM [DE/DE]; Eberhardstrasse 20, D-45661 Recklinghausen (DE).

(74) Representative: BAYER AKTIENGESELLSCHAFT; D-51368 Leverkusen (DE).

(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, EE, HU, IS, JP, KE, KP, KR, KZ, LK, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, UA, US, VN, European Patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With the International Search Report.
Before expiry of the period provided for amending the claims. Further publication will be made if such amendments are received.

As printed

(54) Title: SUGAR-MODIFIED CYTOSTATICS

(54) Bezeichnung: KOHLENHYDRATMODIFIZIERTE CYTOSTATIKA

(57) Abstract

The invention relates to cytostatics which are made tumour-specific by modification with sugar. Suitable spacers ensure serum-stability and intracellular effect at the same time.

(57) Zusammenfassung

Die Erfindung betrifft Cytostatika, die durch Modifikation mit Zucker tumorspezifisch sind. Geeignete Spacer gewährleisten Serumstabilität und gleichzeitig intrazelluläre Wirkung.